A Phase 2 interventional study of [68Ga]CBP8 and Dotarem in Interstitial Lung Disease, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Lung Diseases, Interstitial with a site in United States — 67 open to participants now, 83 under way, 19 of them phase 3. Lung Diseases, Interstitial · United States.
Among the 201 studies in Lung Diseases, Interstitial with a site in United States, this one is the 91st largest by planned enrollment of the 138 interventional ones that give a count, is one of 12 that started in 2022, is one of 52 in phase 2, reaches primary completion later than 16 of the 82 other live ones, and was the 128th registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →67 of the 201 studies in Lung Diseases, Interstitial with a site in United States are open now. Recruiting first, the newest first:
Insmed Incorporated · Sites in United States
Ages 18–85
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+
NS Pharma, Inc. · Sites in United States, Japan
Ages 18–80
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 61 · Phase 3 37 · Phase 4 5
First in 1999; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 53 across the 138 interventional studies, 327 across the 60 observational. Of the 105 that completed or were terminated, 52 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 201 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 1 study filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
25 of the studies in Lung Diseases, Interstitial with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06806592Phase 3Boehringer IngelheimA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | 2027-04-15 |
| NCT05943535Phase 3United TherapeuticsStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 2027-11 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 201 studies in Lung Diseases, Interstitial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.
[68Ga]CBP8, is a PET imaging probe which selectively binds collagen type I. Collagen deposition is a pivotal event in the development of pulmonary fibrosis. [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. In addition, [68Ga]CBP8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis.
The goals of this study are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)
Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22)
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) will receive \[68Ga\]CBP8 and undergo PET-MRI.
Drug: [68Ga]CBP8 · Drug: Dotarem
First degree relatives of a family member with pulmonary fibrosis will receive \[68Ga\]CBP8 and undergo PET-MRI.
Drug: [68Ga]CBP8 · Drug: Dotarem
An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.
Dotarem will be administered during MRI portion of study.
Also known as: gadoterate meglumine
Degree of uptake of [68Ga]CBP8
The degree of uptake of \[68Ga\]CBP8 in the lungs will be compared between groups and associations with disease severity and progression will be determined.
Time frame: 24 months
Rate of MRI contrast clearance, Kwashout, in the lungs
Kwashout rates will be compared between groups and associations with disease severity, progression, and degree of uptake of \[68Ga\]CBP8 will be determined.
Time frame: 24 months
Rate of MRI contrast arrival, Kwashin, in the lungs
Kwashin rates will be compared between groups and associations with disease severity, progression, and degree of uptake of \[68Ga\]CBP8 will be determined.
Time frame: 24 months
Peak enhancement of MRI contrast in the lungs
Peak enhancement will be compared between groups and associations with disease severity, progression, and degree of uptake of \[68Ga\]CBP8 will be determined.
Time frame: 24 months
Plan to share: No
Started Sep 2022 (actual). Primary completion is estimated for Mar 2027, 53 months after the start.
Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 71. This study's planned 53 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CBP-8 gallium GA-68
Massachusetts General Hospital →